Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GAO Tracks Decline In ESA Use Following Regulatory Changes

This article was originally published in The Pink Sheet Daily

Executive Summary

A Government Accountability Office report finds that use of erthryopoiesis-stimulating agents in dialysis decreased 31% from 2007 to the end of 2011 after Medicare’s bundled dialysis payment was changed to include drugs and FDA revised dosing recommendations.

You may also be interested in...

Epogen Use Re-Calculation Drives 9.4% Medicare ESRD Bundled Payment Cut In 2014

CMS was directed by the American Taxpayer Relief Act to “rebase” the ESRD payment level by re-calculating the use of erythropoiesis-stimulating agents and other infused or injectable therapies.

Patient-Reported Outcomes Are Key To Understanding Success of Bundled Payments – NPC’s Dubois

Experience with the end-stage renal disease prospective payment system reveals a valuable lesson – that patient-related quality metrics are needed to fully assess the impact the system has on the patient, something that will be valuable when bundling is considered for treatments where drug costs are significant.

Medicare ESRD Payment Should Account For Epogen Price Increase, Dialysis Centers Say

Dialysis centers write to CMS saying that upcoming Medicare payment cuts for end-stage renal disease treatment, combined with a 5% Epogen price increase, will put “additional pressure on already thin Medicare margins.”

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts